Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
6th
years
Home>>Products>>cas 1208319-27-0 Oclacitinib Maleate(PF-03394197) powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile: +8615207100586

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

cas 1208319-27-0 Oclacitinib Maleate(PF-03394197) powder

CAS NO.1208319-27-0

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,
Contact Supplier

Product Details

Keywords

  • Oclacitinib Maleate
  • Oclacitinib Maleatepowder
  • 99% Oclacitinib Maleate

Quick Details

  • ProName: cas 1208319-27-0 Oclacitinib Maleate(P...
  • CasNo: 1208319-27-0
  • Molecular Formula: C15H22O5
  • Appearance: white
  • Application: Artemisia annua is used as antimalaria...
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Day
  • Purity: 99
  • Storage: room
  • LimitNum: 1 Kilogram

Superiority

cas 1208319-27-0 Oclacitinib Maleate(PF-03394197) powder

Product Name: Oclacitinib Maleate(PF-03394197)
CAS: 1208319-27-0
MF: C19H27N5O6S
MW: 453.51

 

Details

What is oclacitinib maleate

oclacitinib maleate  inhibitor to be developed for dogs. It was recently approved for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. In recent years, there has been a significant evolution in understanding regarding the pathophysiology of allergic and atopic diseases. The molecular mechanisms involved in stimulating the itch response have been elaborated (Marsella et al., 2012), and it is now understood that cytokines play a key role in initiating the neuronal itch stimulation which triggers pruritic behavior (scratching, rubbing, chewing, etc.) in dogs. This leads to the establishment of a vicious cycle of itch that exacerbates skin lesions and amplifies defects in the skin barrier function in clinically affected dogs.

 

Oclacitinib function 

Oclacitinib is labeled to treat atopic dermatitis and itchiness (pruritus) caused by allergies in dogs, though it has also been used to reduce the itchiness and dermatitis caused by flea infestations. It is considered to be highly effective in dogs, and has been established as safe for at least short-term use. Its efficacy equals that of prednisolone at first, though oclacitinib has been found to be more effective in the short term in terms of itchiness and dermatitis, long term safety is unknown. It has been found to have a faster onset and cause less gastrointestinal issues than cyclosporine. While safe in the short term, oclacitinib's long-term safety is unknown. While some say it is best only for acute flares of itchiness, others claim that it is also useful in chronic atopic dermatitis.